At 17.9% CAGR, the Middle East & Africa Organoids Services Market is Projected to be Worth US$ 289.76 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa organoids services market was valued at US$ 91.55 million in 2024 and is expected to reach US$ 289.76 million by 2031, registering a CAGR of 17.9% from 2024 to 2031. Increasing demand for innovative drug screening services and increasing key developments are among the critical factors attributed to driving the Middle East & Africa organoid services market growth.

Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently and avoid costly and time-consuming failures in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services. By creating organoids from a patient's cells, researchers can tailor drug testing to individual responses, improving the likelihood of treatment success through a personalized approach. The integration of advanced technologies, such as high-throughput screening platforms and automated image analysis, further enhances the capabilities of organoid screening services. With the integration of high-throughput screening and organoids, researchers can test many drug compounds efficiently, analyze results more accurately, and accelerate the drug discovery process. Thus, the global focus on innovative screening services, driven by the popularity of personalized medicine and the need for faster drug development, favors the growth of the organoids services market. In January 2024, HUB Organoids (HUB) launched IntegriGut Screen for the global market. This innovative screening service employs patient-derived organoid (PDO) Monolayers-organoid monolayers derived from inflammatory bowel disease (IBD) patients-allowing access to high-quality human data on epithelial barrier function and accelerating the development of novel IBD therapies.

On the contrary, the dearth of skilled professionals hampers the growth of the Middle East & Africa organoids services market.

By type, the Middle East & Africa organoids services market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine held 23.0% share of Middle East & Africa organoids services market share in 2024, amassing US$ 21.02 million. It is projected to garner US$ 65.47 million by 2031 to register 17.6% CAGR during 2024-2031.

By application, the Middle East & Africa organoids services market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease held 30.0% share of Middle East & Africa organoids services market share in 2024, amassing US$ 27.48 million. It is projected to garner US$ 90.48 million by 2031 to register 18.6% CAGR during 2024-2031.

By source, the Middle East & Africa organoids services market is bifurcated into pluripotent stem cells and organ specific adult stem cell. The pluripotent stem cells held 72.6% share of Middle East & Africa organoids services market share in 2024, amassing US$ 66.45 million. It is projected to garner US$ 216.11 million by 2031 to register 18.4% CAGR during 2024-2031

Based on country, the Middle East & Africa organoids services market is categorized into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 33.8% share of Middle East & Africa organoids services market in 2024. It was assessed at US$ 30.98 million in 2024 and is likely to hit US$ 96.64 million by 2031, registering a CAGR of 17.6% during 2024-2031.

Key players operating in the organoids services market are CUSABIO TECHNOLOGY LLC; Cyprio; Eurofins Scientific SE; HUB Organoids B.V. (Hubrecht Organoid Technology); InnoSer; InSphero; LABTOO; Molecular Devices, LLC.; Oncodesign Services; and Sino Biological Inc., among others.

In May 2024: InSphero AG is pleased to announce its exclusive commercialization partnership with Genome Biologics, based in Frankfurt, Germany. This partnership will grant InSphero exclusive global rights to commercialize Genome Biologics' revolutionary 3D Cardiac Organoid Platform. This platform is at the forefront of cardiac disease research, offering precise, scalable, and disease-specific organoid models that are crucial for the development of novel therapeutics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com